4.89

4.12% -0.21

After Hours: 4.77 -0.12 -2.45%

Intensity Therapeutics Inc (INTS)

Overview News Price History Financials Why INTS Down? Discussions Forecast

Intensity Therapeutics Inc stock is currently priced at $4.89, with a 24-hour trading volume of 58,618. It has seen a -4.12% decreased in the last 24 hours and a +24.11% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.06 pivot point. If it approaches the $4.77 support level, significant changes may occur.

Previous Close:

$5.10

Open:

$5.23

24h Volume:

58,618

Market Cap:

$67.05M

Revenue:

Net Income/Loss:

$-10.54M

P/E Ratio:

-2.1628

EPS:

-2.261

Net Cash Flow:

$-7.21M

1W Performance:

+22.25%

1M Performance:

+24.11%

6M Performance:

+132.86%

1Y Performance:

+0.00%

1D Range:

$4.75

$5.275

52W Range:

$2.0101

$11.44

Intensity Therapeutics Inc Stock (INTS) Company Profile

Name

Intensity Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

203 221 7381

Address

61 Wilton Road, 3rd Floor, Westport

Employee

Twitter

Next Earnings Date

Latest SEC Filings

INTS's Discussions on Twitter

Intensity Therapeutics Inc Stock (INTS) Latest News

Manhattan Pioneers Use of GenAI in Supply Chain Commerce - Manchestertimes

Manchestertimes

Tom Bell Joins TSG's Board of Advisors | Business & Finance | manchestertimes.com - Manchestertimes

Manchestertimes

Ex-Alexion CLO Joins Intensity Therapeutics Board - Law360

Law360

Intensity Therapeutics Expands Board, Welcomes New Audit Director - TipRanks.com - TipRanks

TipRanks

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors - PR Newswire

PR Newswire

Intensity Therapeutics: A Bargain Late-Stage Company With Remarkable Oncology Drug (INTS) - Seeking Alpha

Seeking Alpha

Intensity Therapeutics Inc Stock (INTS) Financials Data

Intensity Therapeutics Inc (INTS) Net Income 2024

INTS net income (TTM) was -$10.54 million for the quarter ending December 31, 2023, a -38.99% decrease year-over-year.

Intensity Therapeutics Inc (INTS) Cash Flow 2024

INTS recorded a free cash flow (TTM) of -$7.21 million for the quarter ending December 31, 2023, a -31.55% decrease year-over-year.

Intensity Therapeutics Inc (INTS) Earnings per Share 2024

INTS earnings per share (TTM) was -$1.9334 for the quarter ending December 31, 2023, a -16.25% decline year-over-year.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company was incorporated in 2012 and is headquartered in Westport, Connecticut.